Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB06168_nanopub.RARbWoab9yznhxc9KJ1hdBZ3xAUcEIbRU20ek1FHfFSg4#assertion>. }
Showing items 1 to 18 of
18
with 100 items per page.
- drugbank:DB06168 type drugbank_vocabulary:Drug assertion.
- drugbank:DB06168 label "Canakinumab [drugbank:DB06168]" assertion.
- drugbank:DB06168 seeAlso DB06168 assertion.
- drugbank:DB06168 seeAlso canakinumab.html assertion.
- drugbank:DB06168 seeAlso ilaris-drug.htm assertion.
- drugbank:DB06168 identifier "drugbank:DB06168" assertion.
- drugbank:DB06168 description "Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients." assertion.
- drugbank:DB06168 title "Canakinumab" assertion.
- drugbank:DB06168 bio2rdf_vocabulary:identifier "DB06168" assertion.
- drugbank:DB06168 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB06168 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB06168" assertion.
- drugbank:DB06168 bio2rdf_vocabulary:x-identifiers.org DB06168 assertion.
- drugbank:DB06168 drugbank_vocabulary:drugbank-id "DB06168" assertion.
- drugbank:DB06168 drugbank_vocabulary:x-cas cas:914613-48-2 assertion.
- drugbank:DB06168 drugbank_vocabulary:x-atc atc:L04AC08 assertion.
- drugbank:DB06168 drugbank_vocabulary:x-kegg kegg:D09315 assertion.
- drugbank:DB06168 drugbank_vocabulary:x-wikipedia wikipedia:Canakinumab assertion.
- drugbank:DB06168 drugbank_vocabulary:x-ndc ndc:0078-0582-61 assertion.